Philadelphia, Pennsylvania – First Pharma (“First Pharma”), a private Australian pharmaceutical company operating in the consumer healthcare (“CHC”) segment, has successfully completed the sale of its business to a strategic buyer. First Pharma’s portfolio of products includes proprietary and licensed consumer brands Kenkay®, DermaScar®, Excilor®, Zostrix®, Puranox®, holding leading positions in their CHC categories: skin care, anti-fungal, topical pain, and scar treatments.
Working closely with First Pharma’s management team, Plexus Ventures (“Plexus”) provided comprehensive advisory services throughout the divestment process. Leveraging its deep industry expertise and extensive network of strategic buyers, Plexus facilitated a competitive auction process, ultimately maximizing value for the company’s shareholders.
“First Pharma Board and shareholders are pleased with the final result of this process. The management team have created a solid trajectory of growth for our brands, and we believe this was the right time for new owners to take them to a new level” commented Andrew Howden, Executive Chairman at First Pharma. “Plexus Ventures have been a most professional group to work with. Their experience and processes were valuable in creating the final result.”
“We are delighted to have supported the shareholders and management team of First Pharma in achieving a successful divestment, unlocking significant value for both the company and its new owners,” said Gabriele Tundo, Partner at Plexus Ventures. “This transaction highlights the strength of our healthcare advisory practice and our continued achievements in Australia and the APAC region. We extend our best wishes for the future success of First Pharma brands under its new ownership.”
